Hope for paused AIDS vaccine

Following the recent linkurl:failure;http://www.the-scientist.com/blog/display/53633 of a linkurl:Merck HIV vaccine,;http://www.the-scientist.com/article/display/53517 the NIH has still not decided whether to continue with planned clinical trials of a similar HIV vaccine. Yesterday (December 12), the AIDS Vaccine Research Committee of the National Institute of Allergy and Infectious Diseases met to discuss the PAVE100 study, which was suspended after linkurl:data from the Merck trials;http://w

By | December 13, 2007

Following the recent linkurl:failure;http://www.the-scientist.com/blog/display/53633 of a linkurl:Merck HIV vaccine,;http://www.the-scientist.com/article/display/53517 the NIH has still not decided whether to continue with planned clinical trials of a similar HIV vaccine. Yesterday (December 12), the AIDS Vaccine Research Committee of the National Institute of Allergy and Infectious Diseases met to discuss the PAVE100 study, which was suspended after linkurl:data from the Merck trials;http://www.the-scientist.com/blog/display/53845 came back. Both vaccines use an linkurl:adenovirus vector;http://www.the-scientist.com/article/display/22642 to deliver HIV genes and replicate their proteins. The data from the Merck trials suggested that the vaccine might have actually made people with pre-existing immunity to adenovirus more susceptible to HIV infection, leading to the halting of the PAVE100 trials. The sentiment at yesterday's meeting seemed to be that the vaccines are different enough to warrant going ahead with the PAVE100 study, linkurl:Anthony Fauci,;http://www.the-scientist.com/news/display/53585 the director of the National Institute of Allergy and Infectious Diseases told __The Scientist.__ The PAVE100 vaccine also includes a plasma DNA prime with several additional HIV genes, including envelopes. "The immune response seems to be higher with that strategy and the quality of the immune response seems to be enhanced," Eric Hunter of Emory University, who chairs the AIDS Vaccine Research Committee, told __The Scientist.__ The response to the PAVE100 vaccine includes a greater percentage of multifunctional cd4 and cd8 lymphocytes, Hunter said. The committee suggested that researchers running the PAVE study only test the vaccine in people with no pre-existing immunity to adenovirus, Hunter said. In the Merck trials, that group did not have an increased rate of infection. Whereas the Merck trials got to phase 3, the PAVE study has gone through immunologic trials only, and the clinical studies were slated to begin in late 2007. Fauci said he expects a final decision about the trial to be made at the working group's next meeting in January.

Popular Now

  1. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  2. What Budget Cuts Might Mean for US Science
    News Analysis What Budget Cuts Might Mean for US Science

    A look at the historical effects of downsized research funding suggests that the Trump administration’s proposed budget could hit early-career scientists the hardest.  

  3. Opinion: On “The Impact Factor Fallacy”
  4. Unstructured Proteins Help Tardigrades Survive Desiccation
Business Birmingham